Genome & Company (KOSDAQ:314130)

South Korea flag South Korea · Delayed Price · Currency is KRW
2,560.00
-70.00 (-2.66%)
At close: Aug 28, 2025
-2.66%
Market Cap79.58B
Revenue (ttm)24.02B
Net Income (ttm)-27.08B
Shares Out31.09M
EPS (ttm)-875.69
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume63,775
Average Volume95,703
Open2,630.00
Previous Close2,630.00
Day's Range2,520.00 - 2,645.00
52-Week Range2,170.00 - 4,900.00
Beta1.13
RSI42.85
Earnings DateAug 14, 2025

About Genome & Company

Genome & Company, a clinical stage biotechnology company, researches and develops novel-targeted immuno-oncology therapeutics in the field of immuno-oncology, skin diseases, and autism in South Korea. Its lead product candidate is GEN-001, an oral microbiome therapeutic candidate developed to have immune modulating activities. The company also develops GEN-501 targeting the non-responders of Dupilumab drugs with atopic skin diseases; and GENA-104 for the treatment of solid tumors, as well as microbiome-based products, including therapeutics, co... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2015
Employees 98
Stock Exchange KOSDAQ
Ticker Symbol 314130
Full Company Profile

Financial Performance

In 2024, Genome & Company's revenue was 27.74 billion, an increase of 94.07% compared to the previous year's 14.30 billion. Losses were -20.11 billion, -57.63% less than in 2023.

Financial Statements

News

There is no news available yet.